Established in 2013, the Gilead Genesis Program focuses on health, diagnosis, translational research and technology projects, which contribute to the optimization of clinical practices and the improvement of patients quality of life.
With the high patronage of the President of the Republic, Marcelo Rebelo de Sousa, the pharmaceutical firm distinguished, in its research component, two names of our Medical School, namely Prof. Maria do Carmo Fonseca and Prof. João Forjaz Lacerda both iinside the area of Hemato-oncology.
According to Jornal Expresso , over the six editions, the overall funding allocated to the 76 projects supported by the program has exceeded € 1.5 million, making the Gilead Génese Program one of the most impactful social responsibility initiatives in the health sector in Portugal.
The Gilead Genesis Program distinguished the project Evaluation of the response to sulphonamides (splicing inhibitor) in culture of primary human AML cells , by Prof. Maria do Carmo Fonseca.
Prof. João Forjaz Lacerda was distinguished with the In Vitro Expansion of Receptor Specific T-Regs project in the treatment of chronic graft versus host disease following hematopoietic progenitor cell transplantation.
In this edition, Gilead has distinguished eight research studies and five community intervention projects, not only in the area of Hemato-oncology, but also concerning viral and metabolic hepatitis diseases and HIV / AIDS.
